Kininogens: More than cysteine protease inhibitors and kinin precursors

Biochimie

Volumn 92, Issue 11, 2010, Pages 1568-1579

  Lalmanach, Gilles ^a   Naudin, Clément ^a   Lecaille, Fabien ^a   Fritz, Hans ^b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aging; Angiogenesis; Cathepsin; Cystatin; Cysteine protease; Kininogen

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CATHEPSIN S; CHLOROMETHYLKETONE INHIBITOR; CLINDAMYCIN; COMPLEMENT COMPONENT C1S INHIBITOR; CYSTATIN; CYSTEINE PROTEINASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HIGH MOLECULAR WEIGHT KININOGEN; HKH 20; ICATIBANT; KALLISTATIN; KININ PRECURSOR; KININOGEN; KININOSTATIN; LOW MOLECULAR WEIGHT KININOGEN; PEPTIDE HORMONE; PLASMA KALLIKREIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN PRECURSOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SYNTHETIC PEPTIDE; T KININOGEN; TISSUE KALLIKREIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

AGING; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BLOOD CLOTTING; CANDIDA ALBICANS; CARBOXY TERMINAL SEQUENCE; DRUG POTENCY; ENDOTHELIUM CELL; ENTEROCOCCUS FAECALIS; ENZYME INHIBITOR COMPLEX; ESCHERICHIA COLI; EXPERIMENTAL RAT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INNATE IMMUNITY; KALLIKREIN KININ SYSTEM; LIFESPAN; LUNG HEMORRHAGE; LUNG INFECTION; LUNG LESION; MAMMAL; MITOSIS INHIBITION; NONHUMAN; OSTEOPOROSIS; PHYSICAL CHEMISTRY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PSEUDOMONAS AERUGINOSA; REVIEW; SEPTIC SHOCK; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

MAMMALIA; MUS; NEGIBACTERIA; POSIBACTERIA; RATTUS; STREPTOCOCCUS PYOGENES;

EID: 78149361524     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.011     Document Type: Review

References (211)

1. Muller-Esterl W. Novel functions of the kininogens. Semin. Thromb. Hemost. 1987, 13:115-126.
2. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992, 44:1-80.
3. Kordis D., Turk V. Phylogenomic analysis of the cystatin superfamily in eukaryotes and prokaryotes. BMC Evol. Biol. 2009, 9:266.
4. Abelous J.E., Bardier E. Les substances hypotensives de l'urine humaine normale. C.R. Soc. Biol. 1909, 66:511-512.
5. Kraut H., Frey E.K., Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seyler's Z. Physiol. Chem. 1930, 192:1-21.
6. Rocha E.S.M., Beraldo W.T., Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am. J. Physiol. 1949, 156:261-273.
7. Duncan A.M., Kladis A., Jennings G.L., Dart A.M., Esler M., Campbell D.J. Kinins in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R897-R904.
8. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99:6-38.
9. Proud D., Kaplan A.P. Kinin formation: mechanisms and role in inflammatory disorders. Annu. Rev. Immunol. 1988, 6:49-83.
10. Campbell D.J. The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 2001, 28:1060-1065.
11. Damas J. The novel rat kininogen, T-kininogen. a pro-inflammatory factor or a thiostatin?. Arch. Int. Physiol. Biochim. 1987, 95:67-73.
12. Cyr M., Lepage Y., Blais C., Gervais N., Cugno M., Rouleau J.L., Adam A. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am. J. Physiol. Heart Circ Physiol. 2001, 281:H275-H283.
13. Blais C., Marceau F., Rouleau J.L., Adam A. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000, 21:1903-1940.
14. Campbell D.J. The renin-angiotensin and the kallikrein-kinin systems. Int. J. Biochem. Cell Biol. 2003, 35:784-791.
15. Sainz I.M., Pixley R.A., Colman R.W. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb. Haemost. 2007, 98:77-83.
16. Figueroa C.D., Gonzalez C.B., Muller-Esterl W., Bhoola K.D. Cellular localization of human kininogens. Agents Actions Suppl. 1992, 38(Pt 1):617-626.
17. Hermann A., Buchinger P., Somlev B., Rehbock J. High and low molecular weight kininogen and plasma prekallikrein/plasma kallikrein in villous capillaries of human term placenta. Placenta 1996, 17:223-230.
18. Stuardo M., Gonzalez C.B., Nualart F., Boric M., Corthorn J., Bhoola K.D., Figueroa C.D. Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J. Leukoc. Biol. 2004, 75:631-640.
19. Spragg J., Austen K.F. The preparation of human kininogen. II. Further characterization of purified human kininogen. J. Immunol. 1971, 107:1512-1519.
20. Spragg J., Haber E., Austen K.F. The preparation of human kininogen and the elicitation of antibody for use in a radial immuno-diffusion assay. J. Immunol. 1970, 104:1348-1354.
21. Webster M.E., Pierce J.V. The nature of the kallidins released from human plasma by kallikreins and other enzymes. Ann. N.Y. Acad. Sci. 1963, 104:91-107.
22. Kitamura N., Kitagawa H., Fukushima D., Takagaki Y., Miyata T., Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 1985, 260:8610-8617.
23. Kitamura N., Takagaki Y., Furuto S., Tanaka T., Nawa H., Nakanishi S. A single gene for bovine high molecular weight and low molecular weight kininogens. Nature 1983, 305:545-549.
24. Salvesen G., Parkes C., Abrahamson M., Grubb A., Barrett A.J. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. 1986, 234:429-434.
25. Turk V., Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991, 285:213-219.
26. Turk B., Stoka V., Bjork I., Boudier C., Johansson G., Dolenc I., Colic A., Bieth J.G., Turk V. High-affinity binding of two molecules of cysteine proteinases to low-molecular-weight kininogen. Protein Sci. 1995, 4:1874-1880.
27. Turk V., Stoka V., Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008, 13:5406-5420.
28. Higashiyama S., Ohkubo I., Ishiguro H., Sasaki M., Matsuda T., Nakamura R. Heavy chain of human high molecular weight and low molecular weight kininogens binds calcium ion. Biochemistry 1987, 26:7450-7458.
29. Rawlings N.D., Barrett A.J. Evolution of proteins of the cystatin superfamily. J. Mol. Evol. 1990, 30:60-71.
30. Zhou J., Bjourson A.J., Coulter D.J., Chen T., Shaw C., O'Rourke M., Hirst D.G., Zhang Y., Rao P., McClean S. Bradykinin-related peptides, including a novel structural variant, (Val1)-bradykinin, from the skin secretion of Guenther's frog, Hylarana guentheri and their molecular precursors. Peptides 2007, 28:781-789.
31. Frick I.M., Akesson P., Herwald H., Morgelin M., Malmsten M., Nagler D.K., Bjorck L. The contact system - a novel branch of innate immunity generating antibacterial peptides. EMBO J. 2006, 25:5569-5578.
32. Guo Y.L., Colman R.W. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J. Thromb. Haemost. 2005, 3:670-676.
33. Colman R.W. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des. 2006, 12:2599-2607.
34. Nordahl E.A., Rydengard V., Morgelin M., Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial. J. Biol. Chem. 2005, 280:34832-34839.
35. Cugno M., Scott C.F., Salerno F., Lorenzano E., Muller-Esterl W., Agostoni A., Colman R.W. Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis. Thromb. Haemost. 1999, 82:1428-1432.
36. Colman R.W., Bagdasarian A., Talamo R.C., Scott C.F., Seavey M., Guimaraes J.A., Pierce J.V., Kaplan A.P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 1975, 56:1650-1662.
37. Damas J. The brown Norway rats and the kinin system. Peptides 1996, 17:859-872.
38. Greenbaum L.M., Okamoto H. T-kinin and T-kininogen. Methods Enzymol. 1988, 163:272-282.
39. Urban J., Chan D., Schreiber G. A rat serum glycoprotein whose synthesis rate increases greatly during inflammation. J. Biol. Chem. 1979, 254:10565-10568.
40. Darcy D.A. Response of a serum glycoprotein to tissue injury and necrosis. I. The response to necrosis, hyperplasia and tumour growth. Br. J. Exp. Pathol. 1964, 45:281-293.
41. Esnard F., Gauthier F. Rat alpha 1-cysteine proteinase inhibitor. An acute phase reactant identical with alpha 1 acute phase globulin. J. Biol. Chem. 1983, 258:12443-12447.
42. Moreau T., Gutman N., el Moujahed A., Esnard F., Gauthier F. Relationship between the cysteine-proteinase-inhibitory function of rat T kininogen and the release of immunoreactive kinin upon trypsin treatment. Eur. J. Biochem. 1986, 159:341-346.
43. Sakamoto W., Fujie K., Kaga M., Handa H., Gotoh K., Nishihira J., Kishi J., Hayakawa T., Okada Y. Degradation of T-kininogen by cathepsin D and matrix metalloproteinases. Immunopharmacology 1996, 32:73-75.
44. Lenarcic B., Kos J., Dolenc I., Lucovnik P., Krizaj I., Turk V. Cathepsin D inactivates cysteine proteinase inhibitors, cystatins. Biochem. Biophy. Res. Commun. 1988, 154:765-772.
45. Lenarcic B., Krasovec M., Ritonja A., Olafsson I., Turk V. Inactivation of human cystatin C and kininogen by human cathepsin D. FEBS Lett. 1991, 280:211-215.
46. Gauthier F., Gutman N., Moreau T., el Moujahed A. Possible relationship between the restricted biological function of rat T kininogen (thiostatin) and its behaviour as an acute phase reactant. Biol. Chem. Hoppe Seyler 1988, 369(Suppl.):251-255.
47. Kakizuka A., Kitamura N., Nakanishi S. Localization of DNA sequences governing alternative mRNA production of rat kininogen genes. J. Biol. Chem. 1988, 263:3884-3892.
48. Kaplan A.P., Joseph K., Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 2002, 109:195-209.
49. Muller-Esterl W., Fritz H. Human kininogens and their function in the kallikrein-kinin systems. Adv. Exp. Med. Biol. 1984, 167:41-62.
50. Lundwall A., Band V., Blaber M., Clements J.A., Courty Y., Diamandis E.P., Fritz H., Lilja H., Malm J., Maltais L.J., Olsson A.Y., Petraki C., Scorilas A., Sotiropoulou G., Stenman U.H., Stephan C., Talieri M., Yousef G.M. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 2006, 387:637-641.
51. Colman R.W., Sartor R.B., Adam A.A., DeLa Cadena R.A., Stadnicki A. The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin. Rev. Allergy. Immunol. 1998, 16:365-384.
52. Renne T., Schuh K., Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J. Immunol. 2005, 175:3377-3385.
53. Schmaier A.H., Wahl R., Fisher S.J., Brenner D. The pharmacokinetics of the kininogens. Thromb. Res. 1998, 92:293-297.
54. Pixley R.A., Schapira M., Colman R.W. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 1985, 66:198-203.
55. Gettins P.G. Serpin structure, mechanism, and function. Chem. Rev. 2002, 102:4751-4804.
56. Rau J.C., Beaulieu L.M., Huntington J.A., Church F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 2007, 5(Suppl. 1):102-115.
57. Chao J., Miao R.Q., Chen V., Chen L.M., Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol. Chem. 2001, 382:15-21.
58. Hoffmann H., Siebeck M., Thetter O., Jochum M., Fritz H. Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv. Exp. Med. Biol. 1989, 247B:35-42.
59. Kozik A., Moore R.B., Potempa J., Imamura T., Rapala-Kozik M., Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J. Biol. Chem. 1998, 273:33224-33229.
60. Sato F., Nagasawa S. Kinin release from human LMW-kininogen by the cooperative action of human plasma kallikrein and leukocyte elastase. Adv. Exp. Med. Biol. 1989, 247A:493-498.
61. Higashiyama S., Ishiguro H., Ohkubo I., Fujimoto S., Matsuda T., Sasaki M. Kinin release from kininogens by calpains. Life Sci. 1986, 39:1639-1644.
62. Sasaki M., Kunimatsu M., Ohkubo I. Role of calpains and kininogens in inflammation. Acta Biol. Hung. 1991, 42:231-242.
63. Desmazes C., Galineau L., Gauthier F., Bromme D., Lalmanach G. Kininogen-derived peptides for investigating the putative vasoactive properties of human cathepsins K and L. Eur. J. Biochem. 2003, 270:171-178.
64. Desmazes C., Gauthier F., Lalmanach G. Cathepsin L, but not cathepsin B, is a potential kininogenase. Biol. Chem. 2001, 382:811-815.
65. Puzer L., Vercesi J., Alves M.F., Barros N.M., Araujo M.S., Aparecida Juliano M., Reis M.L., Juliano L., Carmona A.K. A possible alternative mechanism of kinin generation in vivo by cathepsin L. Biol. Chem. 2005, 386:699-704.
66. Lecaille F., Chowdhury S., Purisima E., Bromme D., Lalmanach G. The S2 subsites of cathepsins K and L and their contribution to collagen degradation. Protein Sci. 2007, 16:662-670.
67. Godat E., Lecaille F., Desmazes C., Duchene S., Weidauer E., Saftig P., Bromme D., Vandier C., Lalmanach G. Cathepsin K: a cysteine protease with unique kinin-degrading properties. Biochem. J. 2004, 383:501-506.
68. Veillard F., Lecaille F., Lalmanach G. Lung cysteine cathepsins: Intruders or unorthodox contributors to the kallikrein-kinin system?. Int. J. Biochem. Cell Biol. 2008, 40:1079-1094.
69. Lecaille F., Vandier C., Godat E., Herve-Grepinet V., Bromme D., Lalmanach G. Modulation of hypotensive effects of kinins by cathepsin K. Arch. Biochem. Biophys. 2007, 459:129-136.
70. Couture R., Harrisson M., Vianna R.M., Cloutier F. Kinin receptors in pain and inflammation. Eur. J. Pharmacol. 2001, 429:161-176.
71. Regoli D., Barabe J. Kinin receptors. Methods Enzymol. 1988, 163:210-230.
72. Hecquet C., Tan F., Marcic B.M., Erdos E.G. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 2000, 58:828-836.
73. Katori M., Majima M. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit. Rev. Clin. Lab. Sci. 2003, 40:43-115.
74. Imamura T., Potempa J., Travis J. Activation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases. Biol. Chem. 2004, 385:989-996.
75. Emanueli C., Madeddu P. Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol. Sci. 2001, 22:478-484.
76. Stewart J.M. Bradykinin antagonists: development and applications. Biopolymers 1995, 37:143-155.
77. Stewart J.M., Gera L., York E.J., Chan D.C., Bunn P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology 1999, 43:155-161.
78. Marceau F., Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 2004, 3:845-852.
79. Rawlings N.D., Morton F.R., Kok C.Y., Kong J., Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 2008, 36:D320-D325.
80. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001, 20:4629-4633.
81. Brix K., Dunkhorst A., Mayer K., Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008, 90:194-207.
82. Pillay C.S., Elliott E., Dennison C. Endolysosomal proteolysis and its regulation. Biochem. J. 2002, 363:417-429.
83. Honey K., Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003, 3:472-482.
84. Yang M., Zhang Y., Pan J., Sun J., Liu J., Libby P., Sukhova G.K., Doria A., Katunuma N., Peroni O.D., Guerre-Millo M., Kahn B.B., Clement K., Shi G.P. Cathepsin L activity controls adipogenesis and glucose tolerance. Nat. Cell Biol. 2007, 9:970-977.
85. Maciewicz R.A., Etherington D.J., Kos J., Turk V. Collagenolytic cathepsins of rabbit spleen: a kinetic analysis of collagen degradation and inhibition by chicken cystatin. Coll. Relat. Res. 1987, 7:295-304.
86. Bromme D., Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. 2002, 8:1639-1658.
87. Yasothornsrikul S., Greenbaum D., Medzihradszky K.F., Toneff T., Bundey R., Miller R., Schilling B., Petermann I., Dehnert J., Logvinova A., Goldsmith P., Neveu J.M., Lane W.S., Gibson B., Reinheckel T., Peters C., Bogyo M., Hook V. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9590-9595.
88. Friedrichs B., Tepel C., Reinheckel T., Deussing J., von Figura K., Herzog V., Peters C., Saftig P., Brix K. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 2003, 111:1733-1745.
89. Lecaille F., Kaleta J., Bromme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102:4459-4488.
90. Chiellini C., Costa M., Novelli S.E., Amri E.Z., Benzi L., Bertacca A., Cohen P., Del Prato S., Friedman J.M., Maffei M. Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. J. Cell Physiol. 2003, 195:309-321.
91. Liu Y., Li X., Peng D., Tan Z., Liu H., Qing Y., Xue Y., Shi G.P. Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am. J. Cardiol. 2009, 103:476-481.
92. Taleb S., Lacasa D., Bastard J.P., Poitou C., Cancello R., Pelloux V., Viguerie N., Benis A., Zucker J.D., Bouillot J.L., Coussieu C., Basdevant A., Langin D., Clement K. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 2005, 19:1540-1542.
93. Muller-Esterl W., Fritz H., Machleidt W., Ritonja A., Brzin J., Kotnik M., Turk V., Kellermann J., Lottspeich F. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors. Evidence from immunological, enzymological and sequence data. FEBS Lett. 1985, 182:310-314.
94. Abrahamson M., Ritonja A., Brown M.A., Grubb A., Machleidt W., Barrett A.J. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J. Biol. Chem. 1987, 262:9688-9694.
95. Ohkubo I., Kurachi K., Takasawa T., Shiokawa H., Sasaki M. Isolation of a human cDNA for alpha 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry 1984, 23:5691-5697.
96. Lindahl P., Alriksson E., Jornvall H., Bjork I. Interaction of the cysteine proteinase inhibitor chicken cystatin with papain. Biochemistry 1988, 27:5074-5082.
97. Stubbs M.T., Laber B., Bode W., Huber R., Jerala R., Lenarcic B., Turk V. The refined 2.4 A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 1990, 9:1939-1947.
98. Turk B., Turk V., Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 1997, 378:141-150.
99. Machleidt W., Thiele U., Laber B., Assfalg-Machleidt I., Esterl A., Wiegand G., Kos J., Turk V., Bode W. Mechanism of inhibition of papain by chicken egg white cystatin. Inhibition constants of N-terminally truncated forms and cyanogen bromide fragments of the inhibitor. FEBS Lett. 1989, 243:234-238.
100. 2-terminal 21 amino acid residues are not essential for the papain-inhibitory activity of oryzacystatin, a member of the cystatin superfamily. Expression of oryzacystatin cDNA and its truncated fragments in Escherichia coli. J. Biol. Chem. 1988, 263:7655-7659.
101. Thiele U., Assfalg-Machleidt I., Machleidt W., Auerswald E.A. N-terminal variants of recombinant stefin B: effect on affinity for papain and cathepsin B. Biol. Chem. Hoppe Seyler 1990, 371(Suppl.):125-136.
102. Turk B., Stoka V., Turk V., Johansson G., Cazzulo J.J., Bjork I. High-molecular-weight kininogen binds two molecules of cysteine proteinases with different rate constants. FEBS Lett. 1996, 391:109-112.
103. Lecaille F., Bromme D., Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008, 90:208-226.
104. Moreau T., Esnard F., Gutman N., Degand P., Gauthier F. Cysteine-proteinase-inhibiting function of T kininogen and of its proteolytic fragments. Eur. J. Biochem. 1988, 173:185-190.
105. Vogel R., Assfalg-Machleidt I., Esterl A., Machleidt W., Muller-Esterl W. Proteinase-sensitive regions in the heavy chain of low molecular weight kininogen map to the inter-domain junctions. J. Biol. Chem. 1988, 263:12661-12668.
106. Auerswald E.A., Rossler D., Mentele R., Assfalg-Machleidt I. Cloning, expression and characterization of human kininogen domain 3. FEBS Lett. 1993, 321:93-97.
107. Ylinenjarvi K., Prasthofer T.W., Martin N.C., Bjork I. Interaction of cysteine proteinases with recombinant kininogen domain 2, expressed in Escherichia coli. FEBS Lett. 1995, 357:309-311.
108. Lalmanach G., Hoebeke J., Moreau T., Ferrer-Di Martino M., Gauthier F. An immunochemical approach to investigating the mechanism of inhibition of cysteine proteinases by members of the cystatin superfamily. J. Immunol. Methods 1992, 149:197-205.
109. Gauthier F., Lalmanach G., Moreau T., Borras-Cuesta F., Hoebeke J. Cystatin mimicry by synthetic peptides. Biol. Chem. Hoppe Seyler 1992, 373:465-470.
110. Verdot L., Lalmanach G., Vercruysse V., Hartmann S., Lucius R., Hoebeke J., Gauthier F., Vray B. Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. J. Biol. Chem. 1996, 271:28077-28081.
111. Verdot L., Lalmanach G., Vercruysse V., Hoebeke J., Gauthier F., Vray B. Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur. J. Biochem. 1999, 266:1111-1117.
112. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
113. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
114. Eliceiri B.P., Cheresh D.A. Adhesion events in angiogenesis. Curr. Opin. Cell Bio.l 2001, 13:563-568.
115. Folkman J. Angiogenesis inhibitors generated by tumors. Mol. Med. 1995, 1:120-122.
116. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997, 8:21-43.
117. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
118. Maquart F.X., Bellon G., Pasco S., Monboisse J.C. Matrikines in the regulation of extracellular matrix degradation. Biochimie 2005, 87:353-360.
119. Ortega N., Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J. Cell Sci. 2002, 115:4201-4214.
120. van Hinsbergh V.W., Engelse M.A., Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb. Vasc. Biol. 2006, 26:716-728.
121. Owen C.A. Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int. J. Biochem. Cell Biol. 2008, 40:1246-1272.
122. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
123. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
124. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
125. Gillet L., Roger S., Besson P., Lecaille F., Gore J., Bougnoux P., Lalmanach G., Le Guennec J.Y. Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J. Biol. Chem. 2009, 284:8680-8691.
126. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.Y., Greenbaum D.C., Hager J.H., Bogyo M., Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
127. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20:543-556.
128. Urbich C., Heeschen C., Aicher A., Sasaki K., Bruhl T., Farhadi M.R., Vajkoczy P., Hofmann W.K., Peters C., Pennacchio L.A., Abolmaali N.D., Chavakis E., Reinheckel T., Zeiher A.M., Dimmeler S. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat. Med. 2005, 11:206-213.
129. Turk V., Kos J., Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer?. Cancer Cell 2004, 5:409-410.
130. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
131. Reinheckel T., Hagemann S., Dollwet-Mack S., Martinez E., Lohmuller T., Zlatkovic G., Tobin D.J., Maas-Szabowski N., Peters C. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J. Cell Sci. 2005, 118:3387-3395.
132. Vasiljeva O., Reinheckel T., Peters C., Turk D., Turk V., Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 2007, 13:387-403.
133. Wang B., Sun J., Kitamoto S., Yang M., Grubb A., Chapman H.A., Kalluri R., Shi G.P. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 2006, 281:6020-6029.
134. Schmaier A.H., McCrae K.R. The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 2007, 5:2323-2329.
135. Hayashi I., Amano H., Yoshida S., Kamata K., Kamata M., Inukai M., Fujita T., Kumagai Y., Furudate S., Majima M. Suppressed angiogenesis in kininogen-deficiencies. Lab. Invest. 2002, 82:871-880.
136. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 1993, 265:H586-H592.
137. Ikeda Y., Hayashi I., Kamoshita E., Yamazaki A., Endo H., Ishihara K., Yamashina S., Tsutsumi Y., Matsubara H., Majima M. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 2004, 64:5178-5185.
138. Parenti A., Morbidelli L., Ledda F., Granger H.J., Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001, 15:1487-1489.
139. Knox A.J., Corbett L., Stocks J., Holland E., Zhu Y.M., Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J. 2001, 15:2480-2488.
140. Ishihara K., Hayash I., Yamashina S., Majima M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn. J. Pharmacol. 2001, 87:318-326.
141. Silvestre J.S., Bergaya S., Tamarat R., Duriez M., Boulanger C.M., Levy B.I. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ. Res. 2001, 89:678-683.
142. Colman R.W., Jameson B.A., Lin Y., Johnson D., Mousa S.A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000, 95:543-550.
143. Zhang J.C., Claffey K., Sakthivel R., Darzynkiewicz Z., Shaw D.E., Leal J., Wang Y.C., Lu F.M., McCrae K.R. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 2000, 14:2589-2600.
144. Zhang J.C., Qi X., Juarez J., Plunkett M., Donate F., Sakthivel R., Mazar A.P., McCrae K.R. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can. J. Physiol. Pharmacol. 2002, 80:85-90.
145. Zhang J.C., Donate F., Qi X., Ziats N.P., Juarez J.C., Mazar A.P., Pang Y.P., McCrae K.R. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12224-12229.
146. Al-Fakhri N., Chavakis T., Schmidt-Woll T., Huang B., Cherian S.M., Bobryshev Y.V., Lord R.S., Katz N., Preissner K.T. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol. Chem. 2003, 384:423-435.
147. Sun D., McCrae K.R. Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species. Blood 2006, 107:4714-4720.
148. Wang S., Hasham M.G., Isordia-Salas I., Tsygankov A.Y., Colman R.W., Guo Y.L. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H1917-H1923.
149. Guo Y.L., Wang S., Cao D.J., Colman R.W. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J. Cell Biochem. 2003, 89:622-632.
150. Liu Y., Sainz I.M., Wu Y., Pixley R., Espinola R.G., Hassan S., Khan M.M., Colman R.W. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. Exp. Cell Res. 2008, 314:774-788.
151. Liu Y., Cao D.J., Sainz I.M., Guo Y.L., Colman R.W. The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization. Am. J. Physiol. Cell Physiol. 2008, 295:C257-C267.
152. Katkade V., Soyombo A.A., Isordia-Salas I., Bradford H.N., Gaughan J.P., Colman R.W., Panetti T.S. Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt. Thromb. Haemost. 2005, 94:606-614.
153. Parthasarathy N., Torti S.V., Torti F.M. Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem. J. 2002, 365:279-286.
154. Coffman L.G., Brown J.C., Johnson D.A., Parthasarathy N., D'Agostino R.B., Lively M.O., Hua X., Tilley S.L., Muller-Esterl W., Willingham M.C., Torti F.M., Torti S.V. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294:L505-L515.
155. Coffman L.G., Parsonage D., D'Agostino R., Torti F.M., Torti S.V. Regulatory effects of ferritin on angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:570-575.
156. Vosgerau U., Lauer D., Unger T., Kaschina E. Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells. Biochem. Pharmacol. 2009.
157. Wu Y., Dai J., Schmuckler N.G., Bakdash N., Yoder M.C., Overall C.M., Colman R.W. Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2. J. Thromb. Haemost. 2009.
158. Guo Y.L., Wang S., Colman R.W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1427-1433.
159. Kaufmann J., Haasemann M., Modrow S., Muller-Esterl W. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. J. Biol. Chem. 1993, 268:9079-9091.
160. Herwald H., Morgelin M., Svensson H.G., Sjobring U. Zinc-dependent conformational changes in domain D5 of high molecular mass kininogen modulate contact activation. Eur. J. Biochem. 2001, 268:396-404.
161. Bradford H.N., Dela Cadena R.A., Kunapuli S.P., Dong J.F., Lopez J.A., Colman R.W. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood 1997, 90:1508-1515.
162. Schmaier A.H. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol. 2000, 7:261-265.
163. Mahdi F., Shariat-Madar Z., Kuo A., Carinato M., Cines D.B., Schmaier A.H. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J. Biol. Chem. 2004, 279:16621-16628.
164. Wu Y., Rizzo V., Liu Y., Sainz I.M., Schmuckler N.G., Colman R.W. Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1968-1975.
165. Liu Y., Pixley R., Fusaro M., Godoy G., Kim E., Bromberg M.E., Colman R.W. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 2009, 28:2756-2765.
166. Wachtfogel Y.T., DeLa Cadena R.A., Kunapuli S.P., Rick L., Miller M., Schultze R.L., Altieri D.C., Edgington T.S., Colman R.W. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J. Biol. Chem. 1994, 269:19307-19312.
167. Barbasz A., Guevara-Lora I., Rapala-Kozik M., Kozik A. Kininogen binding to the surfaces of macrophages. Int. Immunopharmacol. 2008, 8:211-216.
168. Chavakis T., Kanse S.M., Lupu F., Hammes H.P., Muller-Esterl W., Pixley R.A., Colman R.W., Preissner K.T. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 2000, 96:514-522.
169. Melo K.R., Gutierrez A., Nascimento F.D., Araujo M.K., Sampaio M.U., Carmona A.K., Coulson-Thomas Y.M., Trindade E.S., Nader H.B., Tersariol I.L., Motta G. Involvement of heparan sulfate proteoglycans in cellular uptake of high molecular weight kininogen. Biol. Chem. 2009, 390:145-155.
170. Renne T., Dedio J., David G., Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 2000, 275:33688-33696.
171. Renne T., Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett. 2001, 500:36-40.
172. Mauron T., Lammle B., Wuillemin W.A. High molecular weight kininogen is cleaved by FXIa at three sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. Thromb. Haemost. 2000, 83:709-714.
173. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
174. Johnson F.B., Sinclair D.A., Guarente L. Molecular biology of aging. Cell 1999, 96:291-302.
175. Friguet B. Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett. 2006, 580:2910-2916.
176. Sierra F., Fey G.H., Guigoz Y. T-kininogen gene expression is induced during aging. Mol. Cell Biol. 1989, 9:5610-5616.
177. Sierra F., Walter R., Vautravers P., Guigoz Y. Identification of several isoforms of T-kininogen expressed in the liver of aging rats. Arch. Biochem. Biophys. 1995, 322:333-338.
178. Sierra F., Coeytaux S., Juillerat M., Ruffieux C., Gauldie J., Guigoz Y. Serum T-kininogen levels increase two to four months before death. J. Biol. Chem. 1992, 267:10665-10669.
179. Acuna-Castillo C., Leiva-Salcedo E., Gomez C.R., Perez V., Li M., Torres C., Walter R., Murasko D.M., Sierra F. T-kininogen: a biomarker of aging in Fisher 344 rats with possible implications for the immune response. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:641-649.
180. Walter R., Murasko D.M., Sierra F. T-kininogen is a biomarker of senescence in rats. Mech. Ageing Dev. 1998, 106:129-144.
181. Keppler D., Sordat B., Sierra F. T-kininogen present in the liver of old rats is biologically active and readily forms complexes with endogenous cysteine proteinases. Mech Ageing Dev. 1997, 98:151-165.
182. Keppler D., Walter R., Perez C., Sierra F. Increased expression of mature cathepsin B in aging rat liver. Cell Tissue Res. 2000, 302:181-188.
183. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.
184. Perez V., Leiva-Salcedo E., Acuna-Castillo C., Aravena M., Gomez C., Sabaj V., Colombo A., Nishimura S., Perez C., Walter R., Sierra F. T-kininogen induces endothelial cell proliferation. Mech. Ageing Dev. 2006, 127:282-289.
185. Kopitar-Jerala N. The role of cystatins in cells of the immune system. FEBS Lett. 2006, 580:6295-6301.
186. Vray B., Hartmann S., Hoebeke J. Immunomodulatory properties of cystatins. Cell Mol. Life Sci. 2002, 59:1503-1512.
187. Leiva-Salcedo E., Perez V., Acuna-Castillo C., Walter R., Sierra F. T-kininogen inhibits kinin-mediated activation of ERK in endothelial cells. Biol. Res. 2002, 35:287-294.
188. Acuna-Castillo C., Aravena M., Leiva-Salcedo E., Perez V., Gomez C., Sabaj V., Nishimura S., Perez C., Colombo A., Walter R., Sierra F. T-kininogen, a cystatin-like molecule, inhibits ERK-dependent lymphocyte proliferation. Mech. Ageing Dev. 2005, 126:1284-1291.
189. Aravena M., Perez C., Perez V., Acuna-Castillo C., Gomez C., Leiva-Salcedo E., Nishimura S., Sabaj V., Walter R., Sierra F. T-kininogen can either induce or inhibit proliferation in Balb/c 3T3 fibroblasts, depending on the route of administration. Mech. Ageing Dev. 2005, 126:399-406.
190. Torres C., Li M., Walter R., Sierra F. Modulation of the ERK pathway of signal transduction by cysteine proteinase inhibitors. J. Cell Biochem. 2000, 80:11-23.
191. Torres C., Li M., Walter R., Sierra F. T-kininogen inhibits fibroblast proliferation in the G(1) phase of the cell cycle. Exp. Cell Res. 2001, 269:171-179.
192. Lam Y.W., Tam N.N., Evans J.E., Green K.M., Zhang X., Ho S.M. Differential proteomics in the aging Noble rat ventral prostate. Proteomics 2008, 8:2750-2763.
193. Kleniewski J., Czokalo M. Plasma kininogen concentration: the low level in cord blood plasma and age dependence in adults. Eur. J. Haematol. 1991, 46:257-262.
194. Hack E., Colman R.W. The role of the contact system in the pathogenesis of septic shock. Sepsis 1999, 3:111-118.
195. Imamura T., Pike R.N., Potempa J., Travis J. Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway. J. Clin. Invest. 1994, 94:361-367.
196. Ben Nasr A., Herwald H., Sjobring U., Renne T., Muller-Esterl W., Bjorck L. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin. Biochem. J. 1997, 326(Pt 3):657-660.
197. Herwald H., Morgelin M., Olsen A., Rhen M., Dahlback B., Muller-Esterl W., Bjorck L. Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat. Med. 1998, 4:298-302.
198. Ben Nasr A.B., Herwald H., Muller-Esterl W., Bjorck L. Human kininogens interact with M protein, a bacterial surface protein and virulence determinant. Biochem. J. 1995, 305(Pt 1):173-180.
199. Rapala-Kozik M., Karkowska J., Jacher A., Golda A., Barbasz A., Guevara-Lora I., Kozik A. Kininogen adsorption to the cell surface of Candida spp. Int. Immunopharmacol. 2008, 8:237-241.
200. Rasmussen M., Bjorck L. Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol. Microbiol. 2002, 43:537-544.
201. Brogden K.A., Guthmiller J.M., Salzet M., Zasloff M. The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 2005, 6:558-564.
202. Andersson E., Rydengard V., Sonesson A., Morgelin M., Bjorck L., Schmidtchen A. Antimicrobial activities of heparin-binding peptides. Eur. J. Biochem. 2004, 271:1219-1226.
203. Frick I.M., Bjorck L., Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb. Haemost. 2007, 98:497-502.
204. Bals R., Wilson J.M. Cathelicidins - a family of multifunctional antimicrobial peptides. Cell Mol. Life Sci. 2003, 60:711-720.
205. Chavakis T., Kanse S.M., Pixley R.A., May A.E., Isordia-Salas I., Colman R.W., Preissner K.T. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J. 2001, 15:2365-2376.
206. Hasan A.A., Cines D.B., Herwald H., Schmaier A.H., Muller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J. Biol. Chem. 1995, 270:19256-19261.
207. Oehmcke S., Shannon O., von Kockritz-Blickwede M., Morgelin M., Linder A., Olin A.I., Bjorck L., Herwald H. Treatment of invasive streptococcal infection with a peptide derived from human high-molecular weight kininogen. Blood 2009, 114:444-451.
208. Persson K., Morgelin M., Lindbom L., Alm P., Bjorck L., Herwald H. Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. J. Exp. Med. 2000, 192:1415-1424.
209. Pasupuleti M., Chalupka A., Morgelin M., Schmidtchen A., Malmsten M. Tryptophan end-tagging of antimicrobial peptides for increased potency against Pseudomonas aeruginosa. Biochim. Biophys. Acta 2009, 1790:800-808.
210. Schmidtchen A., Pasupuleti M., Morgelin M., Davoudi M., Alenfall J., Chalupka A., Malmsten M. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem. 2009, 284:17584-17594.
211. Pasupuleti M., Schmidtchen A., Chalupka A., Ringstad L., Malmsten M. End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. PLoS One 2009, 4:e5285.